Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
20 Julho 2023 - 9:05AM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage
genomic medicine company and Chroma Medicine, Inc. (Chroma), a
genomic medicine company pioneering single-dose epigenetic editing
therapeutics, today announced they have entered into a research
evaluation, option and license agreement to develop epigenetic
medicines leveraging zinc finger proteins (ZFPs) for
sequence-specific DNA recognition. Over the course of two decades,
Sangamo has built and validated the world’s largest library of
ZFPs, deploying them to address numerous therapeutically relevant
targets. Advancing the transformative potential of epigenetic
editing, Chroma is expanding the versatility of its platform by
leveraging Sangamo’s ZFPs. Following a research evaluation period,
Chroma has the option to license the ZFPs for potential worldwide
development and commercialization of epigenetic medicines for
certain therapeutic targets.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230719123616/en/
“Sangamo is the world leader in zinc finger protein genomic
engineering, and we are very proud of the range and depth of our
capabilities in this area,” said Jason Fontenot, Ph.D., Chief
Scientific Officer at Sangamo. “We believe our ability to rapidly
design and engineer highly potent and specific ZFPs can provide
unique and highly valuable capability beyond what is available with
competing technologies. We are constantly seeking to deploy our
technology with partners outside of our core neurology focus area
and are very happy to explore combining our ZF technology with
Chroma’s unique capabilities. We believe that this work will
further validate the importance of zinc fingers as an ideal
platform to support epigenetic editing.”
Under the terms of the agreement, Chroma will evaluate novel
Sangamo ZFPs for specified collaboration targets outside of the
central nervous system in exchange for an upfront technology access
payment. If Chroma exercises its option for any or all targets,
Sangamo would be eligible to receive an option exercise payment, in
addition to potential development and commercial milestone
payments, as well as royalties on any Chroma products incorporating
the licensed ZFPs. Chroma will lead and fund all research,
development, manufacture, and commercialization of products
incorporating the licensed Sangamo ZFPs.
“As a leader in epigenetic editing, Chroma has advanced and
optimized our platform, showing highly efficient, specific, and
durable gene silencing in vivo and the ability to accomplish
multiplex epigenetic editing without induction of indels or
chromosomal rearrangements,” said Vic Myer, Ph.D., President and
Chief Scientific Officer of Chroma. “Leveraging Sangamo’s leading
zinc finger protein engineering capabilities expands our platform
optionality, further positioning Chroma to progress a broad
portfolio of epigenetic editing therapeutics that spans several
indications.”
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical
company with a robust genomic medicines pipeline. Using
ground-breaking science, including our proprietary zinc finger
genome engineering technology and manufacturing expertise, Sangamo
aims to create new genomic medicines for patients suffering from
diseases for which existing treatment options are inadequate or
currently don’t exist. To learn more, visit www.sangamo.com and
connect with us on LinkedIn and Twitter.
About Chroma Medicine, Inc.
Chroma Medicine is a biotechnology company pioneering a new
class of genomic medicines that harness epigenetics, nature’s
innate mechanism for gene regulation, to deliver precise,
programmable single-dose therapeutics while preserving genomic
integrity. The company was founded by the world’s foremost experts
in genomic research and is led by a veteran team of industry
leaders and scientists with deep experience in genomic medicine,
drug discovery, and development. For more information, please visit
chromamedicine.com or follow the company on LinkedIn and
Twitter.
Sangamo Forward Looking Statements
This press release contains forward-looking statements based on
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements relating to Sangamo’s zinc
finger proteins’ potential to be used with Chroma’s epigenetic
editors, the potential for Chroma to develop epigenetic medicines
leveraging ZFPs for sequence-specific DNA recognition, the
potential for Sangamo to provide Chroma specific ZFPs designed for
collaboration targets outside of the central nervous system and for
Sangamo to receive an upfront technology access payment, the
potential for Sangamo to design and engineer ZFPs to provide
valuable capability beyond what is available with competing
technologies, the potential for Chroma to exercise its option and
for Sangamo to receive development and commercial milestone
payments and royalties. These statements are not guarantees of
future performance and are subject to certain risks and
uncertainties that are difficult to predict. Factors that could
cause actual results to differ include, but are not limited to, the
research development process, including the results of clinical
trials; the regulatory approval process for product candidates; and
the potential for technological developments that obviate
technologies used by Sangamo and its partners, the COVID-19
pandemic; the potential for Chroma to breach or terminate its
agreement with Sangamo; and the potential for Sangamo to fail to
realize its expected benefits from the Chroma agreement, including
but not limited to further validating the importance of the zinc
finger platform to support epigenetic editing. Actual results may
differ from those projected in forward-looking statements due to
risks and uncertainties that exist in Sangamo's operations and
business. These risks and uncertainties are described more fully in
our Securities and Exchange Commission filings and reports,
including in our Annual Report on Form 10-K for the year ended
December 31, 2022 and our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2023. Forward-looking statements contained
in this announcement are made as of this date, and Sangamo
undertakes no duty to update such information except as required
under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230719123616/en/
Sangamo Contact Investor Relations & Media Inquiries
Louise Wilkie ir@sangamo.com media@sangamo.com
Chroma Contact Lia Dangelico Verge Scientific
Communications 540.303.0180 ldangelico@vergescientific.com
Sangamo Therapeutics (NASDAQ:SGMO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024